Thrombosis Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Thrombosis stocks.

Thrombosis Stocks Recent News

Date Stock Title
Jul 5 NARI Inari Medical: A Touch Of Uncertainty And Overvaluation
Jul 5 JNJ What's Going On With Johnson and Johnson Shares Friday?
Jul 5 SNY Pharma Stock Roundup: FDA Nod to LLY's Kisunla, SNY's Dupixent Gets EU Nod for COPD
Jul 5 JNJ J&J (JNJ) Trades Below 200 & 50-Day Moving Averages: Buy the Dip?
Jul 5 SNY Dupixent “addresses current gap” in COPD biologics landscape
Jul 4 SNY French State Investment Firm Eyes Stake in Sanofi Consumer Unit
Jul 4 JNJ 3 High-Yield Dividend Stocks/ETFs to Buy Hand Over Fist in July
Jul 3 JNJ Johnson & Johnson receives Canadian approval for Rybrevant in first-line NSCLC
Jul 3 SNY Update: Market Chatter: Bain, Cinven Said to Weigh Joint Bid for Sanofi's Consumer Health Division
Jul 3 SNY Bain, Cinven Weighing Joint Bid for $20 Billion Sanofi Unit
Jul 3 JNJ Johnson & Johnson: A Lot Of Moving Parts, But Perhaps Finally Lurching In The Right Direction
Jul 3 JNJ Johnson & Johnson: Put Selling Can Yield A Potential 9.8% Return
Jul 3 SNY Europe Approves Sanofi/Regeneron's Dupixent for 'Smoker's Lungs' A Month After US FDA Asks For Data
Jul 3 SNY Regeneron (REGN), SNY Win EC Approval for Dupixent for COPD
Jul 3 JNJ How Small Biotech Halozyme, With A 41% Run, Is Getting Under Your Skin
Jul 3 JNJ Health Canada Authorizes RYBREVANT® (amivantamab) in Combination with Carboplatin and Pemetrexed as the Only Targeted First-line Treatment Approved for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Jul 3 JNJ Beacon raises $170M for eye gene therapy; J&J confirms Carvykti survival benefit
Jul 3 SNY Sanofi, Regeneron win EU label expansion for Dupixent in COPD
Jul 3 SNY EMA approves Sanofi’s Dupixent for COPD treatment in adults
Jul 3 SNY Update: Market Chatter: Delaware Judge Rejects Drugmakers' Appeal to End Zantac Lawsuits
Thrombosis

Thrombosis (from Ancient Greek θρόμβωσις thrómbōsis "clotting”) is the formation of a blood clot inside a blood vessel, obstructing the flow of blood through the circulatory system. When a blood vessel (a vein or an artery) is injured, the body uses platelets (thrombocytes) and fibrin to form a blood clot to prevent blood loss. Even when a blood vessel is not injured, blood clots may form in the body under certain conditions. A clot, or a piece of the clot, that breaks free and begins to travel around the body is known as an embolus.Thrombosis may occur in veins (venous thrombosis) or in arteries. Venous thrombosis leads to congestion of the affected part of the body, while arterial thrombosis (and rarely severe venous thrombosis) affects the blood supply and leads to damage of the tissue supplied by that artery (ischemia and necrosis). A piece of either an arterial or a venous thrombus can break off as an embolus which can travel through the circulation and lodge somewhere else as an embolism. This type of embolism is known as a thromboembolism. Complications can arise when a venous thromboembolism (commonly called a VTE) lodges in the lung as a pulmonary embolism. An arterial embolus may travel further down the affected blood vessel where it can lodge as an embolism.

Browse All Tags